527 related articles for article (PubMed ID: 24331576)
21. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
[TBL] [Abstract][Full Text] [Related]
22. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.
Breau RH; Karnes RJ; Farmer SA; Thapa P; Cagiannos I; Morash C; Frank I
BJU Int; 2014 Jun; 113(6):900-6. PubMed ID: 24053569
[TBL] [Abstract][Full Text] [Related]
23. Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume.
Goossens-Laan CA; Visser O; Hulshof MC; Wouters MW; Bosch JL; Coebergh JW; Kil PJ
BJU Int; 2012 Jul; 110(2):226-32. PubMed ID: 22044615
[TBL] [Abstract][Full Text] [Related]
24. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
Nitschke K; Worst TS; von Rhade SM; Thaqi B; Neuberger M; Wessels F; Weis CA; Porubsky S; Gaiser T; Kriegmair M; von Hardenberg J; Weidenbusch M; Erben P; Nuhn P
Urol Oncol; 2021 Aug; 39(8):499.e1-499.e8. PubMed ID: 34134925
[TBL] [Abstract][Full Text] [Related]
25. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
[TBL] [Abstract][Full Text] [Related]
26. Survival after cystectomy for invasive bladder cancer.
de Vries RR; Nieuwenhuijzen JA; Vincent A; van Tinteren H; Horenblas S
Eur J Surg Oncol; 2010 Mar; 36(3):292-7. PubMed ID: 20097512
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent.
Ploeg M; Kums AC; Aben KK; van Lin EN; Smits G; Vergunst H; Viddeleer AC; Geboers AD; van Berkel H; van Boven E; Kiemeney LA; Witjes F
Clin Genitourin Cancer; 2011 Sep; 9(1):14-21. PubMed ID: 21723794
[TBL] [Abstract][Full Text] [Related]
28. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
29. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
30. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
31. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
32. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
[TBL] [Abstract][Full Text] [Related]
33. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.
D'Rummo KA; TenNapel MJ; Shen X
Am J Clin Oncol; 2019 Sep; 42(9):705-710. PubMed ID: 31368905
[TBL] [Abstract][Full Text] [Related]
35. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
[TBL] [Abstract][Full Text] [Related]
36. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
37. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
[TBL] [Abstract][Full Text] [Related]
38. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of the lymphovascular invasion in high-grade stage pT1 bladder cancer.
Branchereau J; Larue S; Vayleux B; Karam G; Bouchot O; Rigaud J
Clin Genitourin Cancer; 2013 Jun; 11(2):182-8. PubMed ID: 23276589
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
